Cartei G, Ceschia T, Marsilio P, Clocchiatti L, Fasola G, Morandini G, Galletti D, Sibau A
Divisione di Oncologia Medica, Ospedale Civile, Udine, Italy.
Tumori. 1989 Jun 30;75(3):229-32. doi: 10.1177/030089168907500308.
From January 1985 to December 1987, 17 patients with advanced malignant melanoma were treated with the polychemotherapy regimen BELD (bleomycin, 15 mg subcutaneously on day 1 and 4, vindesine 3 mg/m2 intravenously on day 1 and 5, CCNU 80 mg/m2 orally on day 1 and DTIC 200 mg/m2 intravenously on day 1 through 5) proposed as effective (CR + PR 45%) and tolerable. All patients were evaluable for toxicity and 14/17 also for response after 2 BELD cycles (total n. of cycles was 54). Criteria for response were just the same as those used by Young et al. A complete remission and a partial remission (2/14) have been observed at lymph nodal level, the unique sites of the disease in these two patients. Remission lasted 6 and 4 months, respectively. Two other patients showed a minimal response of 2 and 3 months duration (lymphonodal and cutis, respectively); 9 patients had stabilized disease of 5 months median duration. One case of progression of disease was observed. However, toxicity was relevant because of 2 early deaths after the first cycle, most probably therapy related, nausea and vomiting (82%), leukopenia (17%) and muscle rigors (11%).
1985年1月至1987年12月，17例晚期恶性黑色素瘤患者接受了联合化疗方案BELD（博来霉素，第1天和第4天皮下注射15mg；长春地辛，第1天和第5天静脉注射3mg/m²；洛莫司汀，第1天口服80mg/m²；达卡巴嗪，第1天至第5天静脉注射200mg/m²）治疗，该方案被认为有效（完全缓解+部分缓解率为45%）且耐受性良好。所有患者均对毒性可进行评估，14/17例患者在接受2个BELD周期治疗后也可评估疗效（总周期数为54个）。疗效标准与Young等人使用的标准相同。在淋巴结水平观察到1例完全缓解和2例部分缓解（2/14），这两名患者的疾病仅发生在淋巴结部位。缓解分别持续6个月和4个月。另外两名患者表现出持续2个月和3个月的微小缓解（分别为淋巴结和皮肤）；9例患者病情稳定，中位持续时间为5个月。观察到1例疾病进展。然而，毒性反应较为严重，因为在第一个周期后有2例早期死亡，很可能与治疗相关，还有恶心和呕吐（82%）、白细胞减少（17%）以及肌肉强直（11%）。
